Company intelligence / Profile preview

Bioenvision

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Bioenvision focused primarily on oncology drug development. Its lead asset was clofarabine, commercialized as Clolar in the US/Canada (Genzyme) and Evoltra in Europe (Bioenvision), approved for relapsed/refractory pediatric acute lymphoblastic leukemia. Other pipeline programs included trilostane and gene therapies, but these were withdrawn or discontinued before acquisition[2][3][4].

Therapeutic areas: OncologyHematologyOther
Modalities: Small moleculeGene therapy
Industry: Biotech

Partnerships

Genzyme (co-development and commercialization of clofarabine)

Beyond the preview

Go deeper on Bioenvision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioenvision.

Explore the full profile